Fmr LLC Trims Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

FMR LLC trimmed its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,830,423 shares of the company's stock after selling 278,718 shares during the quarter. FMR LLC owned 7.46% of Kymera Therapeutics worth $194,328,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its stake in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after purchasing an additional 688,967 shares in the last quarter. Vanguard Group Inc. grew its stake in Kymera Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock worth $196,617,000 after buying an additional 133,546 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Kymera Therapeutics by 5.0% during the fourth quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock valued at $44,484,000 after acquiring an additional 52,263 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Kymera Therapeutics by 5.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after purchasing an additional 20,346 shares in the last quarter. Finally, Schroder Investment Management Group increased its position in shares of Kymera Therapeutics by 14.1% in the 4th quarter. Schroder Investment Management Group now owns 163,896 shares of the company's stock valued at $6,444,000 after acquiring an additional 20,204 shares during the period.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have issued reports on KYMR. Citigroup started coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target for the company. Leerink Partners reaffirmed an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Stephens reaffirmed an "overweight" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded up $0.03 during midday trading on Tuesday, reaching $25.46. 412,126 shares of the company's stock were exchanged, compared to its average volume of 549,220. The firm's 50 day simple moving average is $31.09 and its two-hundred day simple moving average is $39.43. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -10.88 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,659 shares of company stock worth $324,567. Corporate insiders own 15.82% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.